This activity is intended for pediatricians, internists, family medicine and primary care clinicians, public health and prevention officials, nurses, obstetricians/gynecologists, family medicine practitioners, nurses, pharmacists, physician assistants, public health officials, and other members of the healthcare team involved in childhood blood lead level (BLL) testing.
The goal of this activity is for learners to be better able to describe BLL testing trends among young children during the COVID-19 pandemic, according to a Centers for Disease Control and Prevention (CDC) analysis of data reported from 34 state and local health departments about BLL testing among children aged < 6 years conducted during January to May 2019 and January to May 2020.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0 contact hours are in the area of pharmacology.
Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-22-220-H01-P).
Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 7/8/2023. PAs should only claim credit commensurate with the extent of their participation.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 7/8/2022
Valid for credit through: 7/8/2023, 11:59 PM EST
processing....
Note: The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication. We continue to add to the collection of activities on this subject as new information becomes available. It is the policy of Medscape Education to avoid the mention of brand names or specific manufacturers in accredited educational activities. However, manufacturer names related to COVID-19 vaccines may be provided in this activity to promote clarity. The use of manufacturer names should not be viewed as an endorsement by Medscape of any specific product or manufacturer.
The Centers for Disease Control and Prevention (CDC) identify no safe blood lead levels (BLLs) in children and considers a blood lead reference value (BLRV) of 5 μg/dL sufficient to warrant clinical and public health intervention. Among children aged < 6 years, BLLs (> 70 μg/dL) can cause neurologic problems, organ failure, and death.
In the United States, the most common childhood lead exposures are from lead-based paint used in pre-1978 housing, lead-contaminated soil or lead-containing pollutants from industrial sources, and water from old lead pipes and fixtures. Very young children are particularly vulnerable because of their tendency to put fingers or objects in their mouths and their greater absorption of lead as their bodies are rapidly developing.
Childhood BLL testing rates fell by a third in the period March 2020 through September 2020 compared with the same calendar months from 2017 to 2019. Although 2021 testing rates showed some improvement, they were still significantly below prepandemic levels.
The research was presented earlier this month at the 2022 Epidemic Intelligence Service (EIS) Conference,[1] held virtually. EIS is a 2-year epidemiology training program sponsored by the CDC.
Lead exposure in young children can result in serious health consequences, such as brain and nervous system damage, slowed growth, lower IQ, underperformance in school, behavioral issues, and hearing and vision problems. Some of the most common ways children are exposed to lead is lead-based paint chips or lead-contaminated dust, although other sources include soil, drinking water delivered through degrading lead pipes, consumer products such as toys and jewelry, and medicines. Although there is no safe level of lead exposure, the CDC's blood lead reference value (BLRV), which identifies children with the highest blood lead levels, is 3.5 μg/dL.
Lead exposure continues to be an issue of health equity, as children in low-income housing are at a higher risk for lead exposure, according to the CDC.[2] Most children with elevated blood lead levels are asymptomatic, which is why universal screening is recommended, said Hillary Spencer, MD, MPH, an EIS officer at the Chicago Department of Public Health, who presented the research.[1]
"It's similar to the importance of testing someone's blood pressure, because rarely do people have symptoms because of hypertension," she told Medscape Medical News. "You have to test to know."
To find out how the past 2 years of the COVID-19 pandemic have affected childhood blood lead testing, Spencer and her team tallied the total number of lead tests reported to the Illinois Healthy Homes and Lead Poisoning Surveillance System from Chicago children aged 11 months to 4 years. They compared the average number of tests conducted from March through September in the years 2017 to 2019 as well as the total tests performed in the same months in 2020 and 2021.
Spencer's team found that testing levels had dropped 33% in 2020 from prepandemic years, from a mean of 36,307 tests in 2017 to 2019 to 24,387 in 2020. This is consistent with a 34% national drop in childhood blood lead testing that same year, according to a study in the CDC's Morbidity and Mortality Weekly Report.[3] In 2021, the number of tests from March through September rose to 28,622, which was still 21% below the tests performed in prepandemic years.
The results of the study are not particularly surprising, said Alan Woolf, MD, MPH, the director of the Pediatric Environmental Health Center at Boston Children's Hospital, Boston, Massachusetts. He was not involved with the research. "I think it was unreasonable to expect that the level of testing would rise to prepandemic levels in terms of its frequency, at least right away," he told Medscape Medical News.
The pandemic led to a drop-off in people seeking out primary care, which resulted in a decline in BLL testing in Chicago and nationally. There was some improvement in 2021, but in May of that year, a major diagnostic company announced the recall of its point-of-care blood lead test due to unreliable results.[4]
Without that point-of-care testing available in pediatric offices, fewer children ended up getting their BLLs checked.
Beyond prioritizing BLL testing, Woolf said providers can also counsel families to lower risk for lead exposures by:
"We call lead an 'old adversary' but it's still a threat to young children, especially because of its potential effects on their intelligence, learning ability, and behaviors," Woolf said. "Even in 2022, we need to be vigilant and take action to try to lower [exposure]."
Spencer is an officer of the Epidemic Intelligence Service, a program sponsored by the US Centers for Disease Control and Prevention. Woolf reports funding by the Environmental Protection Agency and the Agency for Toxic Substances and Disease Registry.